

Request title: Biologics and Biosimilars

Date of Response: 20th August 2015

Further to your Freedom of Information request, the Trust has answered your questions in the order they appear in your request.

Request

I have a Freedom of Information request regarding biologics and biosimilar prescribing. Could you please provide me with the following numbers of patients treated in the last six months with the following drugs for the conditions listed below.

	Rheumatoid arthritis	Ankylosing spondylitis	Psoriatic arthritis
Abatacept (Orencia)			
Adalimumab (Humira)			
Apremilast (Otezla)			
Certolizumab Pegol (Cimzia)			
Etanercept (Enbrel)			
Golimumab (Simponi)			
Infliximab (Remicade)			
Infliximab biosimilar (Inflectra)			
Infliximab biosimilar (Remsima)			
Rituximab (MabThera)			
Secukinumab (Cosentyx)			
Tocilizumab (RoActemra)			
Ustekinumab (Stelara)			

Reply:

Further to your Freedom of Information request, the Trust has answered your questions in the order they appear in your request in the table below. The Trust is unable to provide data on each of the specific conditions for any of the drugs treatments, but can confirm the numbers of patients receiving each treatment over the last six months i.e. if a patient had rituximab five times they would only be counted once.

Drug	# patients (all conditions)
Abatacept	24
Adalimumab	203
Apremilast	5
Certolizumab	46
Etanercept	67
Golimumab	4
Infliximab (<i>Inflectra</i>)	126
Infliximab (<i>Remicade</i>)	163
Infliximab (<i>Remsima</i>)	8
Rituximab	201
Secukinumab	4
Tocilizumab	35
Ustekinumab	68

- 1) The contracted agreement with the current Fruit and Vegetable supplier is based on an indicative spend of £87,000 for a three year contract (£29,000pa). The actual price paid for these food products is determined by market forces.
- 2) The food is purchased for Patient catering, Retail outlets & functions.